Abstract:Background Gut microbiota and its metabolites are important factors affecting the treatment and progression of ulcerative colitis, but the mechanism was still unclear. This study aims to study the efficacy of Clostridium butyricum MIYAIRI 588 (CBM) on colitis mice and explore the effect on IgA-coated microbiota of CBM and metabolite butyrate. Methods Twenty-four Balb/c mice with specific pathogen-free were randomly divided into four groups of six mice each. The Control group were fed normal drinking water, and the other three groups were drinking water which contained 3% DSS for seven days. In this study, CBM (106CFU/mL) and its main metabolite butyrate (0.2mg/kg) were used to intervene in the colitis mouse by oral gavage. The changes in weight loss, colon length and histopathology of colitis mice were observed and recorded. RNA-sequencing was used to detect the transcriptional changes in the colon in mice, and the percentage of IgA-coated microbiota in feces was detected by flow cytometry. Results From the fourth day after the intervention of CBM and butyrate, the weight loss and colon shorten of colitis mice had been alleviated (IDDF2022-ABS-0275 Figure 1A. Weight loss of mice after CBM and butyrate treatment) (IDDF2022-ABS-0275 Figure 1B. Colon length of mice). Besides, CBM and metabolite butyrate can relieve the colonic pathology, which is reflected in reducing the damage of the mucosa structure and the infiltration of inflammatory cells (IDDF2022-ABS-0275 Figure 1C. Histopathological analysis of colon sections which stained by hematoxylin-eosin staining). RNA-sequencing showed that by KEGG enrichment analysis of differentially expressed genes, numerous signaling pathways concerning immunity and metabolism could be observed, including the pathway of the intestinal immune network for IgA production (IDDF2022-ABS-0275 Figure 1D. KEGG enrichment analysis of butyrate treatment on colitis mice). Furthermore, results showed that the proportion of IgA-coated microbiota in cecal contents of mice with colitis increased significantly. However, both CBM and metabolite butyrate could significantly reduce the proportion of IgA-coated microbiota (IDDF2022-ABS-0275 Figure 1E. The proportion of IgA-coated microbiota after CBM and butyrate treatment) (IDDF2022-ABS-0275 Figure 1F. The statistical analysis of the percentage of IgA-coated microbiota). Conclusions The present study confirmed that CBM and metabolite butyrate could effectively alleviate DSS-induced colitis, might through regulating mucosal immune homeostasis by affecting IgA-coated microbiota. In summary, our study explored the interaction between gut microbiota and host immunity, and it provides theoretical support for the better use of probiotics.

Clostridium Butyricum B1 Alleviates High-Fat Diet-Induced Steatohepatitis in Mice Via Enterohepatic Immunoregulation.

Clostridium Butyricum CGMCC0313.1 Modulates Lipid Profile, Insulin Resistance and Colon Homeostasis in Obese Mice

Front Cover: Clostridium Butyricum Inhibits Fat Deposition Via Increasing the Frequency of Adipose Tissue‐Resident Regulatory T Cells

Microbiota Metabolite Butyrate Differentially Regulates Th1 and Th17 Cells’ Differentiation and Function in Induction of Colitis

Specific Immunotherapy in Combination with Clostridium Butyricum Inhibits Allergic Inflammation in the Mouse Intestine.

Sodium Butyrate Attenuates High-Fat Diet-Induced Steatohepatitis in Mice by Improving Gut Microbiota and Gastrointestinal Barrier.

Effects of Clostridium butyricum and inulin supplementation on intestinal microbial composition in high-fat diet mice

Butyrate Protects Mice Against Methionine–Choline-Deficient Diet-Induced Non-alcoholic Steatohepatitis by Improving Gut Barrier Function, Attenuating Inflammation and Reducing Endotoxin Levels

Butyrate Ameliorated the Intestinal Barrier Dysfunction and Attenuated Acute Pancreatitis in Mice Fed with Ketogenic Diet.

Butyrate Alleviates High Fat Diet-induced Obesity Through Enhancement of Mitochondrial Function in The Liver of Mice

Anti-diabetic Effects of Clostridium butyricum CGMCC0313.1 through Promoting the Growth of Gut Butyrate-producing Bacteria in Type 2 Diabetic Mice

Immunomodulatory effects of Clostridium butyricum on human enterocyte-like HT-29 cells

Supplementation With Sodium Butyrate Modulates The Composition Of The Gut Microbiota And Ameliorates High-Fat Diet-Induced Obesity In Mice

IDDF2022-ABS-0275 Clostridium Btyricum and Metabolite Butyrate Relieve DSS-induced Colitis in Mice by Regulating IGA-coated Microbiota

Clostridium butyricum Strain CCFM1299 Reduces Obesity via Increasing Energy Expenditure and Modulating Host Bile Acid Metabolism

Clostridium Butyricum Alleviates Intestinal Low-Grade Inflammation In Tnbs-Induced Irritable Bowel Syndrome In Mice By Regulating Functional Status Of Lamina Propria Dendritic Cells

Clostridium butyricum Reduces Obesity in a Butyrate-Independent Way

Clostridium butyricum modulates gut microbiota and reduces colitis associated colon cancer in mice

Butyrate Attenuates Hepatic Steatosis Induced by a High-Fat and Fiber-Deficient Diet via the Hepatic GPR41/43-CaMKII/HDAC1-CREB Pathway

Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota

Clostridium butyricum protects intestinal barrier function via upregulation of tight junction proteins and activation of the Akt/mTOR signaling pathway in a mouse model of dextran sodium sulfate-induced colitis